Clinical Professor Phoebe Joy Ho

Clinical Professor
Medicine, Central Clinical School

C39 - Royal Prince Alfred Hospital
The University of Sydney
NSW 2006 Australia

T: +61 2 9515 8031
F: +61 2 9515 8474
E:

On this page

Themes | Keywords | Publications

 

Keywords

Haematological malignancy; Cell biology; Thalassemia; Iron Metabolism

Publications

2013 | 2012 | 2011 | 2010 | 2009 | 2008

2013

   
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, P., Iland, H., Fromm, P., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2013), Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal. 3, e148. [Abstract]

2012

   
  • Ho, P., Brown, R., Spencer, A., Jeffels, M., Daniher, D., Gibson, J., Joshua, D. (2012), Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Leukemia & Lymphoma. 53(9), 1728-1734. [Abstract]
  • Brown, R., Kabani, K., Favaloro, J., Yang, S., Ho, P., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2012), CD86+ or HLA-G+ myeloma cells are associated with poor prognosis and once acquired by trogocytosis create novel Tregacq cells. Blood. 120(10), 2055-2063. [Abstract]
  • Ling, S., Lau, E., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012), Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica. 97(1), 64-72. [Abstract]

2011

   
  • Ho, P., Tay, L., Lindeman, R., Catley, L., Bowden, D. (2011), Australian Guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Internal medicine journal. 41(7), 516-24. [Abstract]
  • Viprakasit, V., Ibrahim, H., Ha, S., Ho, P., Li, C., Chan, L., Chiu, C., Sutcharitchan, P., Habr, D., Domokos, G., Roubert, B., Xue, H., Bowden, D., Lin, K. (2011), Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International Journal of Hematology. 93(3), 319-328. [Abstract]

2010

   
  • Reid, S., Yang, S., Brown, R., Kabani, K., Aklilu, E., Ho, P., Woodland, N., Joshua, D. (2010), Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. International journal of laboratory hematology. 32(6 Pt 1), e190-6. [Abstract]
  • Perera, N., Lau, N., Mathews, S., Waite, C., Ho, P., Caterson, I. (2010), Overview of endocrinopathies associated with β-thalassaemia major. Internal Medicine Journal. 40(10), 689-696. [Abstract]
  • Li, J., Sze, D., Brown, R., Cowley, M., Kaplan, W., Mo, S., Yang, S., Aklilu, E., Kabani, K., Loh, Y., Yamagishi, T., Chen, Y., Ho, P., Joshua, D. (2010), Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom's Macroglobulinaemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood. 115(17), 3580-8. [Abstract]

2009

   
  • Brown, R., Spencer, A., Ho, P., Kennedy, N., Kabani, K., Yang, S., Sze, D., Aklilu, E., Gibson, J., Joshua, D. (2009), Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leukemia and Lymphoma. 50(11), 1860-1864. [Abstract]

2008

   
  • Joshua, D., Brown, R., Ho, P., Gibson, J. (2008), Regulatory T cells and Multiple Myeloma. Clinical Lymphoma & Myeloma. 8(5), 283-286. [Abstract]